TipRanks
Eli Lilly & Co (CH:LLY)
:LLY
Switzerland Market
LLY
Eli Lilly & Co
RESEARCH TOOLSreports

Eli Lilly & Co (LLY) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

LLY Analyst Ratings

Strong Buy
22Ratings
Strong Buy
20 Buy
1 Hold
1 Sell
Based on 22 analysts giving stock ratings to
Eli
Lilly & Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

CHF1,130.08
▲(17.72% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is CHF1,130.08 with a high forecast of CHF1,314.05 and a low forecast of CHF772.00. The average price target represents a 17.72% change from the last price of CHF960.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"579":"CHF579","763":"CHF763","947":"CHF947","1131":"CHF1,131","1315":"CHF1,315"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1314.047504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF1.31K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1130.0808534399998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF1.13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":772.0029086,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF772.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[579,763,947,1131,1315],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,950,978.0036541538461,1006.0073083076923,1034.0109624615384,1062.0146166153845,1090.0182707692306,1118.0219249230768,1146.025579076923,1174.0292332307693,1202.0328873846154,1230.0365415384615,1258.0401956923076,1286.0438498461538,{"y":1314.047504,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,950,963.8523733415384,977.7047466830769,991.5571200246153,1005.4094933661538,1019.2618667076922,1033.1142400492306,1046.9666133907692,1060.8189867323076,1074.671360073846,1088.5237334153844,1102.376106756923,1116.2284800984614,{"y":1130.0808534399998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,950,936.3079160461539,922.6158320923076,908.9237481384615,895.2316641846154,881.5395802307692,867.847496276923,854.1554123230769,840.4633283692308,826.7712444153846,813.0791604615384,799.3870765076922,785.6949925538461,{"y":772.0029086,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":580.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":605.016,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":783.546,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":854.312,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":844.378,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":809.609,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":786.076,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":746.274,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":681.597,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":848.806,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":963.645,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":928.694,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":950,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF1,314Average Price TargetCHF1,130Lowest Price TargetCHF772.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CH:LLY
Umer Raffat
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
09/23/26
Analysts Conflicted on These Healthcare Names: TriSalus Life Sciences (NASDAQ: TLSI) and Eli Lilly & Co (NYSE: LLY)
Jefferies Analyst forecast on CH:LLY
Akash Tewari
Jefferies
Jefferies
CHF1,182.64
Buy
23.19%
Upside
Reiterated
09/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Moderna (NASDAQ: MRNA) and Eli Lilly & Co (NYSE: LLY)
TD Cowen Analyst forecast on CH:LLY
Steve Scala
TD Cowen
TD Cowen
CHF1,026.6
Buy
6.94%
Upside
Reiterated
09/22/26
Analyst Boosts Long-Term Growth Forecasts and Reiterates Buy on Eli Lilly Amid Pipeline and Label Momentum
RBC Capital Analyst forecast on CH:LLY
Trung Huynh
RBC Capital
RBC Capital
CHF1,231.92
Buy
28.32%
Upside
Reiterated
09/21/26
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Wells Fargo Analyst forecast on CH:LLY
Mohit Bansal
Wells Fargo
Wells Fargo
CHF1,092.3
Buy
13.78%
Upside
Reiterated
09/21/26
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and Eli Lilly & Co (NYSE: LLY)
Barclays Analyst forecast on CH:LLY
Emily Field
Barclays
Barclays
CHF1,149.79
Buy
19.77%
Upside
Reiterated
09/21/26
Eli Lilly & Co (LLY) Receives a Buy from Barclays
Guggenheim Analyst forecast on CH:LLY
Seamus Fernandez
Guggenheim
Guggenheim
CHF1,045.49→CHF1,054.52
Buy
9.85%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Leerink Partners Analyst forecast on CH:LLY
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
09/16/26
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and Eli Lilly & Co (NYSE: LLY)
Berenberg Bank Analyst forecast on CH:LLY
Kerry Holford
Berenberg Bank
Berenberg Bank
CHF1,001.96→CHF1,149.79
Buy
19.77%
Upside
Upgraded
09/14/26
Eli Lilly upgraded to Buy from Hold at BerenbergEli Lilly upgraded to Buy from Hold at Berenberg
HSBC Analyst forecast on CH:LLY
Rajesh Kumar
HSBC
HSBC
CHF698.09→CHF772
Sell
-19.58%
Downside
Reiterated
09/10/26
Eli Lilly price target raised to $940 from $850 at HSBCEli Lilly price target raised to $940 from $850 at HSBC
J.P. Morgan Analyst forecast on CH:LLY
Chris Schott
J.P. Morgan
J.P. Morgan
CHF1,149.79
Buy
19.77%
Upside
Reiterated
09/02/26
Eli Lilly Buy Rating Reiterated as Analyst Sees Multi‑Year Growth Upside, Maintains $1,400 December 2026 Price Target
Citi Analyst forecast on CH:LLY
Geoff Meacham
Citi
Citi
CHF1,314.05
Buy
36.88%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Incyte (NASDAQ: INCY) and Eli Lilly & Co (NYSE: LLY)
BMO Capital Analyst forecast on CH:LLY
Evan Seigerman
BMO Capital
BMO Capital
CHF1,149.79
Buy
19.77%
Upside
Reiterated
08/31/26
Analysts' Top Healthcare Picks: Eli Lilly & Co (LLY), Novartis (NVS)
Bernstein Analyst forecast on CH:LLY
Courtney Breen
Bernstein
Bernstein
CHF1,137.47
Buy
18.49%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Eli Lilly & Co (NYSE: LLY) and Rocket Pharmaceuticals (NASDAQ: RCKT)
DBS Analyst forecast on CH:LLY
Nico Chen
DBS
DBS
CHF1,272.98
Buy
32.60%
Upside
Reiterated
08/25/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Eli Lilly & Co (NYSE: LLY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CH:LLY
Umer Raffat
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
09/23/26
Analysts Conflicted on These Healthcare Names: TriSalus Life Sciences (NASDAQ: TLSI) and Eli Lilly & Co (NYSE: LLY)
Jefferies Analyst forecast on CH:LLY
Akash Tewari
Jefferies
Jefferies
CHF1,182.64
Buy
23.19%
Upside
Reiterated
09/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Moderna (NASDAQ: MRNA) and Eli Lilly & Co (NYSE: LLY)
TD Cowen Analyst forecast on CH:LLY
Steve Scala
TD Cowen
TD Cowen
CHF1,026.6
Buy
6.94%
Upside
Reiterated
09/22/26
Analyst Boosts Long-Term Growth Forecasts and Reiterates Buy on Eli Lilly Amid Pipeline and Label Momentum
RBC Capital Analyst forecast on CH:LLY
Trung Huynh
RBC Capital
RBC Capital
CHF1,231.92
Buy
28.32%
Upside
Reiterated
09/21/26
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Wells Fargo Analyst forecast on CH:LLY
Mohit Bansal
Wells Fargo
Wells Fargo
CHF1,092.3
Buy
13.78%
Upside
Reiterated
09/21/26
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and Eli Lilly & Co (NYSE: LLY)
Barclays Analyst forecast on CH:LLY
Emily Field
Barclays
Barclays
CHF1,149.79
Buy
19.77%
Upside
Reiterated
09/21/26
Eli Lilly & Co (LLY) Receives a Buy from Barclays
Guggenheim Analyst forecast on CH:LLY
Seamus Fernandez
Guggenheim
Guggenheim
CHF1,045.49→CHF1,054.52
Buy
9.85%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Leerink Partners Analyst forecast on CH:LLY
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
09/16/26
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and Eli Lilly & Co (NYSE: LLY)
Berenberg Bank Analyst forecast on CH:LLY
Kerry Holford
Berenberg Bank
Berenberg Bank
CHF1,001.96→CHF1,149.79
Buy
19.77%
Upside
Upgraded
09/14/26
Eli Lilly upgraded to Buy from Hold at BerenbergEli Lilly upgraded to Buy from Hold at Berenberg
HSBC Analyst forecast on CH:LLY
Rajesh Kumar
HSBC
HSBC
CHF698.09→CHF772
Sell
-19.58%
Downside
Reiterated
09/10/26
Eli Lilly price target raised to $940 from $850 at HSBCEli Lilly price target raised to $940 from $850 at HSBC
J.P. Morgan Analyst forecast on CH:LLY
Chris Schott
J.P. Morgan
J.P. Morgan
CHF1,149.79
Buy
19.77%
Upside
Reiterated
09/02/26
Eli Lilly Buy Rating Reiterated as Analyst Sees Multi‑Year Growth Upside, Maintains $1,400 December 2026 Price Target
Citi Analyst forecast on CH:LLY
Geoff Meacham
Citi
Citi
CHF1,314.05
Buy
36.88%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Incyte (NASDAQ: INCY) and Eli Lilly & Co (NYSE: LLY)
BMO Capital Analyst forecast on CH:LLY
Evan Seigerman
BMO Capital
BMO Capital
CHF1,149.79
Buy
19.77%
Upside
Reiterated
08/31/26
Analysts' Top Healthcare Picks: Eli Lilly & Co (LLY), Novartis (NVS)
Bernstein Analyst forecast on CH:LLY
Courtney Breen
Bernstein
Bernstein
CHF1,137.47
Buy
18.49%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Eli Lilly & Co (NYSE: LLY) and Rocket Pharmaceuticals (NASDAQ: RCKT)
DBS Analyst forecast on CH:LLY
Nico Chen
DBS
DBS
CHF1,272.98
Buy
32.60%
Upside
Reiterated
08/25/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Eli Lilly & Co (NYSE: LLY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OCULOcular Therapeutix
GHGuardant Health
HROWHarrow Health
DNLIDenali Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months
Geoff MeachamCiti
Success Rate
33/44 ratings generated profit
75%
Average Return
+11.70%
Copying Geoff Meacham's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +11.70% per trade.
1 Year
Geoff MeachamCiti
Success Rate
43/44 ratings generated profit
98%
Average Return
+42.23%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 97.73% of your transactions generating a profit, with an average return of +42.23% per trade.
2 Years
Geoff MeachamCiti
Success Rate
44/44 ratings generated profit
100%
Average Return
+65.22%
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +65.22% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
5
3
2
0
0
Buy
85
84
76
70
62
Hold
2
3
3
4
4
Sell
2
0
0
0
1
Strong Sell
0
0
0
0
0
total
94
90
81
74
67
In the current month, LLY has received 62 Buy Ratings, 4 Hold Ratings, and 1 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,130.08.
Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is CHF8.13 with a range of CHF7.58 to CHF9.28. The previous quarter’s EPS was CHF6.88. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.
Next quarter’s earnings estimate for LLY is CHF8.13 with a range of CHF7.58 to CHF9.28. The previous quarter’s EPS was CHF6.88. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is CHF18.30B with a range of CHF17.55B to CHF19.73B. The previous quarter’s sales results were CHF18.86B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.
Next quarter’s sales forecast for LLY is CHF18.30B with a range of CHF17.55B to CHF19.73B. The previous quarter’s sales results were CHF18.86B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Stock Forecast FAQ

What is CH:LLY’s average 12-month price target, according to analysts?
Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,130.08.
    What is CH:LLY’s upside potential, based on the analysts’ average price target?
    Eli Lilly & Co has 17.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Eli Lilly & Co a Buy, Sell or Hold?
          Eli Lilly & Co has a consensus rating of Strong Buy, which is based on 20 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Eli Lilly & Co’s share price target?
            The average share price target for Eli Lilly & Co is 1,130.08. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF1,314.05 ,and the lowest forecast is CHF772.00. The average share price target represents 17.72% Increase from the current price of CHF960.
              What do analysts say about Eli Lilly & Co?
              Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Eli Lilly & Co?
                To buy shares of CH:LLY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.